Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adrenocortical Cancer
Malignant adrenocortical tumors can be identified immunohistochemically using IGFII and MIB1
October 25th, 2006
The differentiation of benign from malignant adrenocortical tumours can be accomplished using IGFII and MIB1 are helpful immunohistochemical markers. According to recent research published in the journal Histopathology, "The differentiation of adrenocortical carcinomas from adenomas may be difficult based on morphology alone. Differential expression of insulin-like growth factor (IGF) II and cyclin-dependent kinase (CDK) 4 has recently been described in these tumours. The aim of this study was to investigate the diagnostic usefulness of these markers immunohistochemically." A. Schmitt and colleagues at the University of Zurich "examined 22...
Source: Biotech Week (2006-10-25)
|
